Siemens to acquire Bayer Diagnostics arm

21300 Investors following Siemens. Share this News with them.

0

Like this story, share it with millions of investors on M3

Siemens to acquire Bayer Diagnostics arm

Siemens to acquire Bayer Diagnostics arm – Medical Solutions Group further expands position in key high-growth molecular diagnostics market.

Post your opinion here

 

0

Tweet

Share on Tumblr

Siemens has signed an agreement with Bayer to acquire the chemical and pharmaceutical company's Diagnostics Division. The acquisition will enable Siemens Medical Solutions (Med) to expand its position in the high-growth molecular diagnostics market. At the end of April, Siemens announced the planned acquisition of Diagnostic Products Corporation (DPC) in the U.S., a leading company in immunodiagnostics. The purchase price for Bayer Diagnostics - which had sales of €1.4 billion and a double-digit EBITDA margin in fiscal 2005 - is roughly €4.2 billion.

"Demographic change is greatly increasing global demand for healthcare services and thereby generating excellent growth opportunities for Siemens," explained Dr. Klaus Kleinfeld, Siemens President and CEO. "The acquisition of Bayer Diagnostics is part of our targeted strategy to create the healthcare industry's first integrated diagnostics company by combining the entire imaging diagnostics, laboratory diagnostics and clinical IT value chain under one roof." Kleinfeld also noted that this acquisition, which is subject to regulatory approval, is - like other purchases in the last few quarters - further proof that Siemens is rigorously focusing its portfolio on promising growth fields.

Dr. Erich R. Reinhardt, member of the Siemens Managing Board and President of Siemens' Medical Solutions Group, commented: "Molecular medicine is becoming increasingly important since it enables healthcare professionals to identify the causes of disease using genetic profiles. With the help of molecular medicine, it will be possible not only to predict the effects of the medications selected and tailor treatment for individual patients, but also to diagnose disease at an early stage. The planned acquisition of DPC has provided us with access to laboratory diagnostics. With the acquisition of Bayer Diagnostics, we will now have a comprehensive portfolio in this key future-oriented market. These deals will enable us to considerably expand our range of expertise and further our leading position as a trendsetter in healthcare."

The two acquisitions will make Siemens Medical Solutions No. 2 worldwide in immunodiagnostics. In addition, the acquisition of the Bayer unit will enable the Siemens Group to tap the rapidly growing market for molecular diagnostics based on gene analysis (nucleid acid testing). Bayer Diagnostics is also a world market-leader in clinical chemistry with a leading position in near-patient testing, laboratory automation and hematology (blood cell diagnostics).

"We are convinced that the successful laboratory equipment business has even better prospects in a company specializing in medical technology. The decision to divest our Diagnostics Division is fully in line with our strategy for systematically aligning our healthcare business. We are concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients," commented Bayer AG Management Board Chairman Werner Wenning.

Siemens Medical Solutions develops products and services that improve recovery rates by diagnosing diseases earlier and more accurately. Its goal is to enable its customers to increase healthcare quality while improving efficiency. Siemens is an innovations driver in diagnostic imaging systems (in-vivo diagnostics) and the market leader in healthcare IT. The company strengthened its position in molecular in-vivo diagnostics last year through the acquisition of CTI, delivering increased capabilities in the development and manufacture of positron emission tomography (PET) systems that can be used, for example, in the diagnosis of cancer and Alzheimer's disease, in addition to advanced development of new molecular contrast agents and pharmaceutical tracers.

The acquisitions of DPC and Bayer Diagnostics are expected to fuel further innovations that will considerably improve the quality of healthcare through early, specific and efficient diagnostic solutions.

Sourced From : Vaishnavi Corporate Communications